Compare Citius Pharmaceuticals Inc (CTXR) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs PepsiCo, Inc. — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while PepsiCo, Inc. trades at $136.81 (market cap $184.87B). The key difference: PepsiCo, Inc. is far larger — about 12627.7× Citius Pharmaceuticals Inc's market cap, and PepsiCo, Inc. pays a 4.37% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | PEP | |
|---|---|---|
Market Cap | $14.64M | $184.87B |
Sector | Health | Consumer Staples |
52-Week High | $1.82 | $170.44 |
52-Week Low | $0.53 | $133.81 |
Enterprise Value | $10.86M | $227.37B |
Dividend Yield | — | 4.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
PepsiCo (PEP) trades at $136.03, down 1.78% for the day, with a bearish technical signal and mixed sentiment. The stock shows strong profitability with a 10.78% net margin and 51.59% ROE, though revenue growth remains modest. Recent news highlights price adjustments for snacks after consumer pushback on high costs, while analyst consensus leans Hold with a $159.27 price target.
The outlook is cautious near-term due to technical weakness and pricing challenges, but fundamentals support long-term stability. Risks include competitive pressures and margin compression, while opportunities lie in operational improvements and dividend reliability. Investors should weigh current volatility against the company's solid cash flow and market position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
